Cargando…
Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045586/ https://www.ncbi.nlm.nih.gov/pubmed/36979858 http://dx.doi.org/10.3390/biomedicines11030879 |
_version_ | 1784913640597487616 |
---|---|
author | Ramírez-Coronel, Andrés Alexis Rostami, Amirabbas Younus, Laith A. Arias Gonzáles, José Luis Lafta, Methaq Hadi Amin, Ali H. Saadoon, Mohammed Abdulkadhim Salman, Hayder Mahmood Bahrami, Abolfazl Feilei, Rossa Akhavan-Sigari, Reza |
author_facet | Ramírez-Coronel, Andrés Alexis Rostami, Amirabbas Younus, Laith A. Arias Gonzáles, José Luis Lafta, Methaq Hadi Amin, Ali H. Saadoon, Mohammed Abdulkadhim Salman, Hayder Mahmood Bahrami, Abolfazl Feilei, Rossa Akhavan-Sigari, Reza |
author_sort | Ramírez-Coronel, Andrés Alexis |
collection | PubMed |
description | Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets and identified hub high-traffic genes. We also investigated whether the expressions of PLK1 were altered in the chorionic villi collected from women with RPL compared to those from healthy early pregnant women. Gene expression differences were evaluated using both pathway and gene ontology (GO) analyses. The identified genes were validated using in vivo and in vitro models. Mice with PLK1-overexpression and PLK1-knockdown in vitro models were produced by transfecting certain plasmids and si-RNA, respectively. The apoptosis in the chorionic villi, mitochondrial function, and NF-κB signaling activity was evaluated. To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered. The HTR-8/SVneo and JEG-3 cell lines were chosen to establish an RPL model in vitro. The NF-κB signaling, Foxo signaling, PI3K/AKT, and endometrial cancer signaling pathways were identified via the RPL regulatory network. The following genes were identified: PLK1 as hub high-traffic gene and MMP2, MMP9, BAX, MFN1, MFN2, FOXO1, OPA1, COX15, BCL2, DRP1, FIS1, TRAF2, and TOP2A. Clinical samples were examined, and the results demonstrated that RPL patients had tissues with decreased PLK1 expression in comparison to women with normal pregnancies (p < 0.01). In vitro, PLK1 knockdown induced the NF-κB signaling pathway and apoptosis activation while decreasing cell invasion, migration, and proliferation (p < 0.05). Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic. |
format | Online Article Text |
id | pubmed-10045586 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100455862023-03-29 Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches Ramírez-Coronel, Andrés Alexis Rostami, Amirabbas Younus, Laith A. Arias Gonzáles, José Luis Lafta, Methaq Hadi Amin, Ali H. Saadoon, Mohammed Abdulkadhim Salman, Hayder Mahmood Bahrami, Abolfazl Feilei, Rossa Akhavan-Sigari, Reza Biomedicines Article Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets and identified hub high-traffic genes. We also investigated whether the expressions of PLK1 were altered in the chorionic villi collected from women with RPL compared to those from healthy early pregnant women. Gene expression differences were evaluated using both pathway and gene ontology (GO) analyses. The identified genes were validated using in vivo and in vitro models. Mice with PLK1-overexpression and PLK1-knockdown in vitro models were produced by transfecting certain plasmids and si-RNA, respectively. The apoptosis in the chorionic villi, mitochondrial function, and NF-κB signaling activity was evaluated. To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered. The HTR-8/SVneo and JEG-3 cell lines were chosen to establish an RPL model in vitro. The NF-κB signaling, Foxo signaling, PI3K/AKT, and endometrial cancer signaling pathways were identified via the RPL regulatory network. The following genes were identified: PLK1 as hub high-traffic gene and MMP2, MMP9, BAX, MFN1, MFN2, FOXO1, OPA1, COX15, BCL2, DRP1, FIS1, TRAF2, and TOP2A. Clinical samples were examined, and the results demonstrated that RPL patients had tissues with decreased PLK1 expression in comparison to women with normal pregnancies (p < 0.01). In vitro, PLK1 knockdown induced the NF-κB signaling pathway and apoptosis activation while decreasing cell invasion, migration, and proliferation (p < 0.05). Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic. MDPI 2023-03-13 /pmc/articles/PMC10045586/ /pubmed/36979858 http://dx.doi.org/10.3390/biomedicines11030879 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ramírez-Coronel, Andrés Alexis Rostami, Amirabbas Younus, Laith A. Arias Gonzáles, José Luis Lafta, Methaq Hadi Amin, Ali H. Saadoon, Mohammed Abdulkadhim Salman, Hayder Mahmood Bahrami, Abolfazl Feilei, Rossa Akhavan-Sigari, Reza Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches |
title | Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches |
title_full | Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches |
title_fullStr | Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches |
title_full_unstemmed | Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches |
title_short | Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches |
title_sort | designing effective multi-target drugs and identifying biomarkers in recurrent pregnancy loss (rpl) using in vivo, in vitro, and in silico approaches |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045586/ https://www.ncbi.nlm.nih.gov/pubmed/36979858 http://dx.doi.org/10.3390/biomedicines11030879 |
work_keys_str_mv | AT ramirezcoronelandresalexis designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT rostamiamirabbas designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT younuslaitha designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT ariasgonzalesjoseluis designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT laftamethaqhadi designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT aminalih designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT saadoonmohammedabdulkadhim designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT salmanhaydermahmood designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT bahramiabolfazl designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT feileirossa designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches AT akhavansigarireza designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches |